Peptic Ulcer Hemorrhage

3
Pipeline Programs
4
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%

On Market (1)

Approved therapies currently available

U
PANTOPRAZOLE SODIUMApproved
pantoprazole
Unknown Company
oral2016

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
1
PantoprazolePhase 3Small Molecule1 trial
PantoprazolePhase 2Small Molecule1 trial
Active Trials
NCT00037570Completed12Est. Feb 2002
NCT00040495Completed149Est. Jan 2003

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerPantoprazole
PfizerPantoprazole

Clinical Trials (2)

Total enrollment: 161 patients across 2 trials

NCT00040495PfizerPantoprazole

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

Start: Apr 2001Est. completion: Jan 2003149 patients
Phase 3Completed
NCT00037570PfizerPantoprazole

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

Start: Nov 2000Est. completion: Feb 200212 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space